# Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

> **NCT06317649** · PHASE2 · RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 147 (estimated)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Azacitidine
- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Bone Marrow Aspiration
- **PROCEDURE:** Bone Marrow Biopsy
- **DRUG:** Gilteritinib
- **DRUG:** Venetoclax

## Key facts

- **NCT ID:** NCT06317649
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-27
- **Primary completion:** 2029-05-15
- **Final completion:** 2029-05-15
- **Target enrollment:** 147 (ESTIMATED)
- **Last updated:** 2026-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06317649

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06317649, "Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT06317649. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*